Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Comparison of the 2021 COVID-19 ‘Roadmap’ Projections against Public Health Data

View ORCID ProfileMatt J. Keeling, View ORCID ProfileLouise Dyson, View ORCID ProfileMichael J. Tildesley, View ORCID ProfileEdward M. Hill, View ORCID ProfileSamuel Moore
doi: https://doi.org/10.1101/2022.03.17.22272535
Matt J. Keeling
1The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, School of Life Sciences and Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK
2Joint UNIversities Pandemic and Epidemiological Research,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matt J. Keeling
  • For correspondence: m.j.keeling@warwick.ac.uk
Louise Dyson
1The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, School of Life Sciences and Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK
2Joint UNIversities Pandemic and Epidemiological Research,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Louise Dyson
Michael J. Tildesley
1The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, School of Life Sciences and Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK
2Joint UNIversities Pandemic and Epidemiological Research,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael J. Tildesley
Edward M. Hill
1The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, School of Life Sciences and Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK
2Joint UNIversities Pandemic and Epidemiological Research,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Edward M. Hill
Samuel Moore
1The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, School of Life Sciences and Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK
2Joint UNIversities Pandemic and Epidemiological Research,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Samuel Moore
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Control and mitigation of the COVID-19 pandemic in England has relied on a combination of vaccination and non-pharmaceutical interventions (NPIs) such as closure of non-essential shops and leisure activities, closure of schools, social distancing, mask wearing, testing followed by isolation and general public health awareness. Some of these measures are extremely costly (both economically and socially), so it is important that they are relaxed promptly but without overwhelming already burdened health services. The eventual policy was a Roadmap of four relaxation steps throughout 2021, taking England from lock-down to the cessation of all restrictions on social interaction; with a minimum of five weeks between each step to allow the data to reflect the changes in restrictions and the results to analysed. Here we present a retrospective analysis of our six Roadmap documents generated in 2021 to assess the likely impacts of future relaxation steps in England. In each case we directly compare results generated at the time with more recent public health data (primarily hospital admissions, but also hospital occupancy and death) to understand discrepancies and potential improvements. We conclude that, in general, the model projections generated a reliable estimation of medium-term hospital admission trends, with the data points up to September 2021 generally lying within our 95% projection intervals. The greatest uncertainties in the modelled scenarios came from estimates of vaccine efficacy, hampered by the lack of data in the early stages of the Alpha and Delta variant waves, and from assumptions about human behaviour in the face of changing restrictions and changing risk. These are clearly avenues for future study.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

MJK, LD and MJT were supported through the JUNIPER modelling consortium [grant number MR/V038613/1]; MJK and SM were supported by the National Institute for Health Research (NIHR) [Policy Research Programme, Mathematical and Economic Modelling for Vaccination and Immunisation Evaluation, and Emergency Response; NIHR200411]; MJK, LD, MJT and EMH were supported by the Medical Research Council through the COVID-19 Rapid Response Rolling Call [grant number MR/V009761/1] MJK is affiliated to the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections at University of Liverpool in partnership with UK Health Security Agency (UKHSA), in collaboration with University of Warwick. MJK is also affiliated to the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Genomics and Enabling Data at University of Warwick in partnership with UK Health Security Agency (UKHSA). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care or UK Health Security Agency.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Data from the CHESS and SARI databases were supplied after anonymisation under strict data protection protocols agreed between the University of Warwick and Public Health England. The ethics of the use of these data for these purposes was agreed by Public Health England with the Governments SPI-M(O) / SAGE committees.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data on cases were obtained from the COVID-19 Hospitalisation in England Surveillance System (CHESS) data set that collects detailed data on patients infected with COVID-19. Data on COVID-19 deaths were obtained from Public Health England. These data contain confidential information, with public data deposition non-permissible for socioeconomic reasons. The CHESS data resides with the National Health Service (www.nhs.gov.uk) whilst the death data are available from Public Health England (www.phe.gov.uk). The ethics of the use of these data for these purposes was agreed by Public Health England with the Governments SPI-M(O) / SAGE committees. More aggregate data is freely available from the UK Coronavirus dashboard: https://coronavirus.data.gov.uk/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 18, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of the 2021 COVID-19 ‘Roadmap’ Projections against Public Health Data
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Comparison of the 2021 COVID-19 ‘Roadmap’ Projections against Public Health Data
Matt J. Keeling, Louise Dyson, Michael J. Tildesley, Edward M. Hill, Samuel Moore
medRxiv 2022.03.17.22272535; doi: https://doi.org/10.1101/2022.03.17.22272535
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Comparison of the 2021 COVID-19 ‘Roadmap’ Projections against Public Health Data
Matt J. Keeling, Louise Dyson, Michael J. Tildesley, Edward M. Hill, Samuel Moore
medRxiv 2022.03.17.22272535; doi: https://doi.org/10.1101/2022.03.17.22272535

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (412)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (156)
  • Dermatology (97)
  • Emergency Medicine (247)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (392)
  • Epidemiology (8542)
  • Forensic Medicine (4)
  • Gastroenterology (383)
  • Genetic and Genomic Medicine (1741)
  • Geriatric Medicine (167)
  • Health Economics (371)
  • Health Informatics (1235)
  • Health Policy (618)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (371)
  • Infectious Diseases (except HIV/AIDS) (10274)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1668)
  • Nursing (97)
  • Nutrition (248)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (925)
  • Ophthalmology (263)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (111)
  • Palliative Medicine (40)
  • Pathology (251)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (246)
  • Primary Care Research (207)
  • Psychiatry and Clinical Psychology (1760)
  • Public and Global Health (3829)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (318)
  • Respiratory Medicine (518)
  • Rheumatology (207)
  • Sexual and Reproductive Health (165)
  • Sports Medicine (156)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (100)
  • Urology (74)